Medscape is available in 5 Language Editions – Choose your Edition here.


Renal Corticomedullary Abscess Medication

  • Author: Aaron Benson, MD; Chief Editor: Edward David Kim, MD, FACS  more...
Updated: Dec 06, 2015

Medication Summary

The goals of pharmacotherapy are to eradicate the infection, to reduce morbidity, and to prevent complications.



Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Piperacillin and tazobactam sodium (Zosyn)


Antipseudomonal penicillin plus beta-lactamase inhibitor. Inhibits biosynthesis of cell wall mucopeptide and is effective during active multiplication stage.

Ticarcillin and clavulanate (Timentin)


Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active growth. Antipseudomonal penicillin plus beta-lactamase inhibitor that provides coverage against most gram-positive organisms, most gram-negative organisms, and most anaerobes.

Nafcillin (Nafcil, Nallpen, Unipen)


Initial therapy for suspected penicillin G–resistant streptococcal or staphylococcal infections.

Use parenteral therapy initially in severe infections. Change to PO therapy as condition warrants.

Because of thrombophlebitis, particularly in the elderly, administer parenterally only for short term (1-2 d); change to PO route as clinically indicated.

Ceftazidime (Fortaz)


Third-generation cephalosporin with broad-spectrum, gram-negative activity, including Pseudomonas species; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms. Arrests bacterial growth by binding to one or more penicillin-binding proteins, which, in turn, inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall synthesis, thus inhibiting cell wall biosynthesis. The condition of the patient, severity of the infection, and susceptibility of the microorganism should determine the proper dose and route of administration.

Cefepime (Maxipime)


Fourth-generation cephalosporin. Gram-negative coverage comparable to that of ceftazidime but has better gram-positive coverage (comparable to ceftriaxone). Cefepime is a zwitter ion; rapidly penetrates gram-negative cells. Best beta-lactam drug for IM administration. Poor capacity to cross blood-brain barrier precludes use for treatment of meningitis.

Ciprofloxacin (Cipro)


Fluoroquinolone that inhibits bacterial DNA synthesis and, consequently, growth by inhibiting DNA gyrase and topoisomerases, which are required for replication, transcription, and translation of genetic material. Quinolones have broad activity against gram-positive and gram-negative aerobic organisms. Has no activity against anaerobes. Continue treatment for at least 2 d (7-14 d typical) after signs and symptoms have disappeared.

Levofloxacin (Levaquin)


For pseudomonal infections and infections due to multidrug-resistant gram-negative organisms.

Gentamicin (Garamycin)


Aminoglycoside antibiotic for gram-negative coverage bacteria, including Pseudomonas species. Synergistic drug with beta-lactamase against enterococci. Interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits.

Dosing regimens are numerous and are adjusted based on CrCl and changes in volume of distribution, as well as body space into which agent needs to distribute. Dose of gentamicin may be given IV/IM. Each regimen must be followed by at least trough level drawn on third or fourth dose, 0.5 h before dosing; may draw peak level 0.5 h after 30-min infusion.

Amikacin (Amikin)


Irreversibly binds to 30S subunit of bacterial ribosomes; blocks recognition step in protein synthesis; causes growth inhibition. For gram-negative bacterial coverage of infections resistant to gentamicin and tobramycin. Effective against Pseudomonas aeruginosa.

Use patient's IBW for dosage calculation. The same principles of drug monitoring for gentamicin apply to amikacin.

Tobramycin (Nebcin)


Aminoglycoside antibiotic for gram-negative coverage. Used in combination with both an agent against gram-positive organisms and one that covers anaerobes.

Contributor Information and Disclosures

Aaron Benson, MD Staff Physician, Department of Urology, Southern Illinois University School of Medicine

Aaron Benson, MD is a member of the following medical societies: American Medical Association, American Urological Association, Illinois State Medical Society

Disclosure: Nothing to disclose.


Keith Steinbecker, MD Consulting Staff, Department of Urology, St John's Mercy Medical Center

Keith Steinbecker, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.

Julius Lynn Teague, MD, FACS, FAAP Medical Director, Pediatric Urology, Greenville Hospital System Children's Hospital

Julius Lynn Teague, MD, FACS, FAAP is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, American Urological Association, Christian Medical and Dental Associations

Disclosure: Nothing to disclose.

Thomas H Tarter, MD, PhD Associate Professor, Department of Surgery, Division of Urology, Director of Urologic Oncology, Simmons Cooper Cancer Institute, Southern Illinois University School of Medicine

Thomas H Tarter, MD, PhD is a member of the following medical societies: American Medical Association, American Urological Association, Society of Urologic Oncology, American College of Surgeons Oncology Group

Disclosure: Received ownership interest from Illinois Cryotherapy Enterprise for other.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Shlomo Raz, MD Professor, Department of Surgery, Division of Urology, University of California, Los Angeles, David Geffen School of Medicine

Shlomo Raz, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, California Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Edward David Kim, MD, FACS Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, Tennessee Medical Association, Sexual Medicine Society of North America, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Repros.

  1. Baradkar VP, Mathur M, Kumar S. Renal abscess due to Escherichia coli in a child. Saudi J Kidney Dis Transpl. 2011 Nov. 22(6):1215-8. [Medline].

  2. Bitsori M, Raissaki M, Maraki S, Galanakis E. Acute focal bacterial nephritis, pyonephrosis and renal abscess in children. Pediatr Nephrol. 2015 Nov. 30 (11):1987-93. [Medline].

  3. Dubey D, Raza FS, Sawhney A, Pandey A. Klebsiella pneumoniae Renal Abscess Syndrome: A Rare Case with Metastatic Involvement of Lungs, Eye, and Brain. Case Rep Infect Dis. 2013. 2013:685346. [Medline]. [Full Text].

  4. Linder BJ, Granberg CF. Pediatric renal abscesses: A contemporary series. J Pediatr Urol. 2015 Sep 16. [Medline].

  5. Huisman TK, Sands JP. Focal xanthogranulomatous pyelonephritis associated with renal cell carcinoma. Urology. 1992 Mar. 39(3):281-4. [Medline].

  6. Ko MC, Chiu AW, Liu CC, Liu CK, Woung LC, Yu LK, et al. Effect of diabetes on mortality and length of hospital stay in patients with renal or perinephric abscess. Clinics (Sao Paulo). 2013. 68(8):1109-14. [Medline]. [Full Text].

  7. Velciov S, Gluhovschi G, Trandafirescu V, Petrica L, Bozdog G, Gluhovschi C, et al. Specifics of the renal abscess in nephrology: observations of a clinic from a county hospital in Western Romania. Rom J Intern Med. 2011. 49(1):59-66. [Medline].

  8. Vourganti S, Agarwal PK, Bodner DR, et al. Ultrasonographic evaluation of renal infections. Radiol Clin N Am. November 2006. 44:763-75. [Medline].

  9. Fontanilla T, Minaya J, Cortés C, Hernando CG, Arangüena RP, Arriaga J, et al. Acute complicated pyelonephritis: contrast-enhanced ultrasound. Abdom Imaging. 2011 Jul 27. [Medline].

  10. Claes H, Vereecken R, Oyen R, et al. Xanthogranulomatous pyelonephritis with emphasis on computerized tomography scan. Retrospective study of 20 cases and literature review. Urology. 1987 Apr. 29(4):389-93. [Medline].

  11. Dalla Palma L, Pozzi-Mucelli F, Ene V. Medical treatment of renal and perirenal abscesses: CT evaluation. Clin Radiol. 1999 Dec. 54(12):792-7. [Medline].

  12. Kawashima A, Sandler CM, Ernst RD, et al. Renal inflammatory disease: the current role of CT. Crit Rev Diagn Imaging. 1997 Oct. 38(5):369-415. [Medline].

  13. Comploj E, Cassar W, Farina A, Gasparella P, Trenti E, Palermo S, et al. Conservative management of paediatric renal abscess. J Pediatr Urol. 2013 Jun 20. [Medline].

  14. Abdul-Halim H, Kehinde EO, Abdeen S, et al. Severe emphysematous pyelonephritis in diabetic patients: diagnosis and aspects of surgical management. Urol Int. 2005. 75(2):123-8. [Medline].

  15. Alan C, Ataus S, Tunç B. Xanthogranulamatous pyelonephritis with psoas abscess: 2 cases and review of the literature. Int Urol Nephrol. 2004. 36(4):489-93. [Medline].

  16. Anderson KA, McAninch JW. Renal abscesses: classification and review of 40 cases. Urology. 1980 Oct. 16(4):333-8. [Medline].

  17. Brook I. Urinary tract and genito-urinary suppurative infections due to anaerobic bacteria. Int J Urol. 2004 Mar. 11(3):133-41. [Medline].

  18. Chen J, Koontz WW. Inflammatory lesions of the kidney. AUA Update Series. 1995. XIV(26):210-216.

  19. Cheng CH, Tsau YK, Lin TY. Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics. 2006 Jan. 117(1):e84-9. [Medline].

  20. Coelho RF, Schneider-Monteiro ED, Mesquita JL, et al. Renal and perinephric abscesses: analysis of 65 consecutive cases. World J Surg. February 2007. 31:431-6. [Medline].

  21. Corriere JN Jr, Sandler CM. The diagnosis and immediate therapy of acute renal and perirenal infections. Urol Clin North Am. 1982 Jun. 9(2):219-28. [Medline].

  22. Dembry LM. Renal and perirenal abscesses. Curr Treat Options Infect Dis. 2002. 4:21-30.

  23. Dembry LM, Andriole VT. Renal and perirenal abscesses. Infect Dis Clin North Am. 1997 Sep. 11(3):663-80. [Medline].

  24. Demertzis J, Menias CO. State of the art: imaging of renal infections. Emerg Radiol. 2007 Apr. 14(1):13-22. [Medline].

  25. Forland M, Thomas V, Shelokov A. Urinary tract infections in patients with diabetes mellitus. Studies on antibody coating of bacteria. JAMA. 1977 Oct 31. 238(18):1924-6. [Medline].

  26. Geeting GK, Shaikh N. Renal abscess. J Emerg Med. 2006 Jul. 31(1):99-100. [Medline].

  27. Malek RS, Elder JS. Xanthogranulomatous pyelonephritis: a critical analysis of 26 cases and of the literature. J Urol. 1978 May. 119(5):589-93. [Medline].

  28. Meares EM. Nonspecific infections of the genitourinary tract. Tanagho EA, McAnich JW, eds. Smith's General Urology. New York, NY: McGraw-Hill; 1995. 201-44.

  29. Medical Economics Company. Physician's Desk Reference. 54th ed. 2000.

  30. Olazabal A, Velasco M, Martinez A, et al. Emphysematous pyelonephritis. Urology. 1987 Jan. 29(1):95-8. [Medline].

  31. Patel NP, Lavengood RW, Fernandes M, et al. Gas-forming infections in genitourinary tract. Urology. 1992 Apr. 39(4):341-5. [Medline].

  32. Patterson JE, Andriole VT. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am. 1997 Sep. 11(3):735-50. [Medline].

  33. Petronic V, Buturovic J, Isvaneski M. Xanthogranulomatous pyelonephritis. Br J Urol. 1989 Oct. 64(4):336-8. [Medline].

  34. Rinder MR. Renal abscess: an illustrative case and review of the literature. Md Med J. 1996 Oct. 45(10):839-43. [Medline].

  35. Roberts JA. Management of pyelonephritis and upper urinary tract infections. Urol Clin North Am. 1999 Nov. 26(4):753-63. [Medline].

  36. Roberts JA. Pyelonephritis, cortical abscess, and perinephric abscess. Urol Clin North Am. 1986 Nov. 13(4):637-45. [Medline].

  37. Rubenstein JN, Schaeffer AJ. Managing complicated urinary tract infections: the urologic view. Infect Dis Clin North Am. 2003 Jun. 17(2):333-51. [Medline].

  38. Schaeffer AJ. Infections of the urinary tract. Campbell MF, Retik AB, eds. Campbell's Urology. 7th ed. Philadelphia, Pa: WB Saunders and Co; 1998. 533-614.

  39. Secil M, Gulcu A, Goktay AY, et al. Renal corticomedullary abscess. J Emer Med. January 2007. 32:119-21. [Medline].

  40. Seidel T, Kuwertz-Broking E, Kaczmarek S, et al. Acute focal bacterial nephritis in 25 children. Pediatr Nephrol. November 2007. 22:1897-1901. [Medline].

  41. Stamm WE, Hooton TM, Johnson JR, et al. Urinary tract infections: from pathogenesis to treatment. J Infect Dis. 1989 Mar. 159(3):400-6. [Medline].

  42. Yen DH, Hu SC, Tsai J, et al. Renal abscess: early diagnosis and treatment. Am J Emerg Med. 1999 Mar. 17(2):192-7. [Medline].

  43. Weerakkody RM, Palangasinghe DR, Wadanambi S, Wijewikrama ES. "Primary" nocardial brain abscess in a renal transplant patient. BMC Res Notes. 2015 Nov 23. 8 (1):701. [Medline].

  44. Sharma A, Singh D. Scedosporium apiospermum causing brain abscess in a renal allograft recipient. Saudi J Kidney Dis Transpl. 2015 Nov-Dec. 26 (6):1253-6. [Medline].

Contrasted CT scan that demonstrates a corticomedullary abscess in a 27-year-old patient with diabetes mellitus who has a history of multiple urinary tract infections. Note the heterogeneous hypodense lesion in the right kidney. Extracapsular extension is not present.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.